ANTXHealthcare · BiotechnologyThe 2 Wall Street analysts covering AN2 Therapeutics, Inc. hold a median 12-month price target of $9 — +91.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 29 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AN2 Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Growth (31): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ANTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +91.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | Guggenheim | Initiates | Buy | $9.00 |
| 14 May 2026 | Leerink Partners | Upgrade | Outperform | $9.00 |
| 14 May 2026 | Leerink Partners | Upgrade | Outperform | — |
| 5 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 26 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 25 Feb 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 3 Feb 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 19 Nov 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 18 Nov 2024 | TD Cowen | Downgrade | Hold | — |
| 9 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
| 3 July 2024 | Leerink Partners | Upgrade | Outperform | — |
| 16 May 2024 | Evercore ISI Group | Maintains | In-Line | — |
| 2 Apr 2024 | JMP Securities | Upgrade | Market Outperform | — |
| 1 Apr 2024 | Oppenheimer | Reiterates | Perform | — |
| 13 Feb 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 12 Feb 2024 | Evercore ISI Group | Downgrade | In-Line | — |
| 12 Feb 2024 | JMP Securities | Downgrade | Market Perform | — |
| 12 Feb 2024 | Oppenheimer | Downgrade | Perform | — |
| 4 Jan 2024 | JMP Securities | Initiates | Market Outperform | — |
| 30 Mar 2023 | Oppenheimer | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ANTX appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, AN2 Therapeutics, Inc. returned +260.8% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 89% of US stocks
Cheaper than 40% of US stocks
Cheaper than 75% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AN2 Therapeutics, Inc. has a market value of $170.6M and an enterprise value of $92.2M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$36.3M.
Diluted earnings per share, trailing twelve months: $−1.07.
Free cash flow in the twelve months to 30 June 2026: −$30.7M.
Trailing P/E: −3.9×; forward P/E: −5.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
AN2 Therapeutics, Inc. employs 21 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AN2 Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AN2 Therapeutics announced inducement equity awards for two newly hired employees. The October 19, 2026 grants included options to purchase 10,565 shares of common stock; the excerpt ends before specifying the full award details.
Why it matters — The announcement provides information about equity compensation granted to new hires under the listing-rule inducement provision.
AN2 Therapeutics announced it will present a poster detailing the design of its planned Phase 2 trial evaluating epetraborole in patients with polycythemia vera. The poster will be presented at the 18th International Congress on Myeloproliferative Neoplasms, held October 29–30.
Why it matters — The presentation provides an update on AN2’s planned clinical evaluation of epetraborole in polycythemia vera.
AN2 Therapeutics announced that management will participate in three investor conferences in November. The excerpt identifies the Guggenheim 3rd Annual Healthcare Innovation Conference, scheduled for November 9–11, 2026, and names CEO Eric Easom as a participant.
Why it matters — ANTX watchers may note the scheduled opportunity for company management to engage with investors.
Purcell & Lefkowitz LLP announced an investigation of AN2 Therapeutics on behalf of shareholders. It is examining whether directors breached fiduciary duties in connection with recent corporate actions.
Why it matters — The investigation concerns the conduct of ANTX’s directors and the company’s recent corporate actions.
AN2 Therapeutics announced that the Gates Foundation has awarded an extension of funding to support AN2's research activities under its ongoing tuberculosis research collaboration with GSK, which focuses on developing boron-based leucyl-tRNA synthetase (LeuRS) inhibitors.
Why it matters — The extended Gates Foundation funding provides continued support for AN2's TB collaboration with GSK, helping sustain research progress in its boron chemistry platform.
The 2 Wall Street analysts covering AN2 Therapeutics, Inc. have a median 12-month price target of $9, with estimates ranging from $9 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering AN2 Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AN2 Therapeutics, Inc. 71 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, AN2 Therapeutics, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +91.9% from the last close, and Ticker Nerd's factor model ranks AN2 Therapeutics, Inc. 71 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AN2 Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $9 over the next 12 months.
AN2 Therapeutics, Inc. returned +260.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform.
The most recent item we track (Business Wire, 23 Oct 2026): "AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)". AN2 Therapeutics announced inducement equity awards for two newly hired employees. The October 19, 2026 grants included options to purchase 10,565 shares of common stock; the excerpt ends before specifying the full award details.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s current pipeline includes programs in infectious diseases, hematologic disorders, and oncology, with research efforts aimed at addressing serious and rare conditions with high unmet medical needs. Its product candidates include oral therapies under development for diseases such as Chagas disease, non-tuberculous mycobacterial lung disease, and other infectious disease targets, alongside earlier-stage oncology and global health programs. AN2 Therapeutics operates as a drug discovery and development business, advancing its candidates through preclinical and clinical studies to support potential future therapies for patients and healthcare providers.
CEO Mr. Eric E. Easom · 21 employees · United States · https://www.an2therapeutics.com
